trending Market Intelligence /marketintelligence/en/news-insights/trending/XOfbs5HgpnEWjv-MYJvcIA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Recordati's Isturisa wins EU nod to treat rare hormonal disorder

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Recordati's Isturisa wins EU nod to treat rare hormonal disorder

Recordati Industria Chimica e Farmaceutica SpA's experimental drug Isturisa, or osilodrostat, has been approved by the European Commission to treat a rare hormonal disorder called Cushing's syndrome.

Isturisa was previously backed by a European Medicines Agency committee to treat the disorder, a severe endocrine disease caused by an enlargement in the pituitary gland that results in overproduction of the body's main stress hormone called cortisol.

The Italian pharmaceutical company, which acquired worldwide rights to Isturisa through a $390 million deal with Novartis AG in October 2019, will get 10 years of market exclusivity with orphan-drug status that was granted with the EU approval.

The agency's approval is based on a study called Linc-3, which showed that Isturisa was better than placebo in controlling cortisol levels in patients with Cushing's syndrome, meeting the trial's primary goal.